Mizuho Markets Americas LLC Has $5.85 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Mizuho Markets Americas LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,089 shares of the company's stock after selling 5,453 shares during the quarter. Mizuho Markets Americas LLC's holdings in Johnson & Johnson were worth $5,849,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Meridian Financial Partners LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $1,626,000. Lmcg Investments LLC boosted its position in shares of Johnson & Johnson by 32.7% in the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company's stock worth $14,125,000 after purchasing an additional 21,471 shares during the last quarter. WealthPlan Investment Management LLC grew its stake in shares of Johnson & Johnson by 7.3% during the third quarter. WealthPlan Investment Management LLC now owns 61,691 shares of the company's stock worth $9,998,000 after purchasing an additional 4,174 shares during the period. Cooper Haims Advisors LLC boosted its holdings in Johnson & Johnson by 6.4% during the first quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company's stock worth $531,000 after buying an additional 201 shares during the last quarter. Finally, Trajan Wealth LLC increased its stake in shares of Johnson & Johnson by 11.3% in the 3rd quarter. Trajan Wealth LLC now owns 32,992 shares of the company's stock valued at $5,347,000 after acquiring an additional 3,341 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $2.13 during mid-day trading on Friday, reaching $154.00. 11,328,515 shares of the company's stock were exchanged, compared to its average volume of 6,621,219. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $370.77 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53. The business's fifty day simple moving average is $161.35 and its two-hundred day simple moving average is $156.10. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.66 EPS. Analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday. They set an "outperform" rating and a $190.00 price target on the stock. Morgan Stanley upped their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and dropped their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $175.94.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.